Facet Says Yes To Abbott's $720 Million Buyout Offer
This article was originally published in The Pink Sheet Daily
Executive Summary
The antibody specialist said no to Biogen Idec in December and found a better offer of nearly $10 more a share.
You may also be interested in...
PDL Aims To Acquire New Royalty Assets Before Current Licenses Expire
PDL BioPharma has been preparing for the expiry of key patents by making a few hires and reconfiguring its business, with plans to use remaining cash either to purchase new royalty bearing assets or, failing that, to wind up the business.
Abbott Refreshes Rheumatoid Arthritis Strategy By Licensing Biotest's Phase II Candidate
For $85 million up-front in a deal potentially worth $480 million, Abbott gets a mid-stage antibody that could be a possible successor to strong-selling Humira.
Abbott Refreshes Rheumatoid Arthritis Strategy By Licensing Biotest's Phase II Candidate
For $85 million up-front in a deal potentially worth $480 million, Abbott gets a mid-stage antibody that could be a possible successor to strong-selling Humira.